Skip to main content

Advertisement

Fabrication of Hybrid Nanostructures Based on Fe3O4 Nanoclusters as Theranostic Agents for Magnetic Resonance Imaging and Drug Delivery

Article metrics

  • 711 Accesses

  • 1 Citations

Abstract

Combining anticancer drugs with inorganic nanocrystals to construct multifunctional hybrid nanostructures has become a powerful tool for cancer treatment and tumor suppression. However, it remains a critical challenge to synthesize compact, multifunctional nanostructures with improved functionality and reproducibility. In this study, we report the fabrication of magnetite hybrid nanostructures employing Fe3O4 nanoparticles (NPs) to form multifunctional magnetite nanoclusters (NCs) by combining an oil-in-water microemulsion assembly and a layer-by-layer (LBL) method. The Fe3O4 NCs were firstly prepared via a microemulsion self-assembly technique. Then, polyelectrolyte layers composed of poly(allylamine hydrochloride) (PAH) and poly(sodium 4-styrenesulfonate) (PSS) and doxorubicin hydrochloride (DOX) were capped on Fe3O4 NCs to construct the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures via LBL method. The as-prepared hybrid nanostructures loaded with DOX demonstrated the pH-responsive drug release and higher cytotoxicity towards human lung cancer (A549) cells in vitro and can serve as T2-weighted magnetic resonance imaging (MRI) contrast agents, which can significantly improve T2 relaxivity and lead to a better cellular MRI contrast effect. The loaded DOX emitting red signals under excitation with 490 nm are suitable for bioimaging applications. This work provides a novel strategy to build a Fe3O4-based multifunctional theranostic nanoplatform with T2-weighted MRI, fluorescence imaging, and drug delivery.

Introduction

In recent years, various multifunctional drug delivery systems have been developed for future diagnosis and therapy in biomedical application [1,2,3,4]. Multifunctional hybrid nanostructures that are integrated favorable properties will possess significant applications such as multimodal imaging and simultaneous diagnosis and therapy [5,6,7,8,9,10,11]. Furthermore, these nanostructures are stimuli-responsive drug delivery systems for improved drug accumulation, enhanced therapeutic efficacy, and/or reduced side effects. Especially, these pH-responsive drug delivery systems have attracted extensive research interest. This is because most human tumors have a more acidic pH value, which provides a possible way to design the controlled release of drug molecules [12,13,14,15,16].

Over the past few decades, various hybrid nanostructures by combining inorganic nanomaterials with organic polymer [17,18,19,20] have been developed, including magnetic particles [21,22,23], upconversion nanoparticles (NPs) [17, 24], and mesoporous silica particles [25]. Among those, magnetic hybrid nanostructures based on iron oxides with relatively large magnetization at room temperature have been widely used in the biomedical fields [26,27,28,29]. The functionalization of inorganic nanomaterials coated with polyelectrolyte layers can realize a pH-responsive encapsulation and release of drug molecules [12, 17, 30]. More recently, the polyelectrolyte layers composed of sodium poly (styrene sulfonate) (PSS) and the polycation poly(allylamine hydrochloride) (PAH) has been widely studied [31,32,33,34,35,36]. Polyelectrolyte layers combined with magnetic and luminescent NPs or drug molecules for multifunctional drug delivery systems have also been recently reported [37,38,39]. Iron oxide (Fe3O4) NPs are getting more and more attention in the field of magnetic resonance imaging (MRI) and drug delivery due to their unique superparamagnetic properties, biocompatibility, low-cytotoxicity, and flexibility [9, 11, 28, 29, 40,41,42]. In general, there are two methods to improve the magnetic responsiveness of Fe3O4 NPs. The first one is to synthesize the micrometer-sized magnetite particles. Due to large size, however, they tend to aggregate in aqueous solution, which is not beneficial to biomedical applications. The other approach is to assemble Fe3O4 NPs into nanoclusters (NCs). These Fe3O4 NCs greatly improved the magnetic responsiveness compared to individual Fe3O4 NPs [22, 43]. Therefore, if the self-assembled Fe3O4 NCs are adopted as the core to fabricate multifunctional hybrid nanostructures, the MRI performance will be improved by the collective effect of Fe3O4 NPs [43,44,45]. To our knowledge, the self-assembled Fe3O4 NCs functionalized with PAH/PSS multilayers for pH-responsive drug release have rarely been reported.

In this work, a versatile theranostic nanoplatform based on Fe3O4 NPs was built up for MRI and drug delivery. In our approach, Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were obtained by combining an oil-in-water microemulsion method and a layer-by-layer (LBL) electrostatic adsorption method. It is expected that the packed Fe3O4 NC system can lead to enhanced T2 relaxivity and imaging contrast, and the large specific surface area of Fe3O4 NC/PAH/PSS hybrid nanostructures allows high loading of anticancer drugs. Moreover, in vitro experiment exhibits that the cellular MRI contrast of human lung cancer (A549) cells incubated with Fe3O4 NC/PAH/PSS/DOX has been significantly enhanced.

Materials and Methods

Materials

FeCl3·6H2O (99.99%), FeCl2·4H2O (99.99%), oleic acid (OA, 90%), and 1-octadecene (ODE, 90%) were purchased from Alfa Aeasar. Sodium oleate (NaOA), ethanol, hexane, cyclohexane, isopropanol, sodium dodecyl benzene sulfonate (SDBS), ammonium fluoride (NH4F), sodium hydroxide (NaOH), dimethyl sulfoxide (DMSO), and ammonia were purchased from Sinopharm Chemical Reagent Co., Ltd (China). Poly(allylamine hydrochloride) (PAH), poly(styrene sulfonate) (PSS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide were purchased from Sigma-Aldrich. Anticancer drug doxorubicin hydrochloride (DOX, > 98%) was purchased from Shanghai Sangon Biotech Company (Shanghai, China). APMI 1640 growth medium and fetal bovine serum (FBS) were purchased from Hyclone. All reagents were used as received without further purification.

Preparation of Ferric Oleate

The synthesis of magnetic NPs started from the synthesis of ferric oleate. FeCl3·6H2O (2.59 g), NaOA (14.6 g), C2H5OH (32 mL), H2O (24 mL), and hexane (56 mL) were mixed together in a 150-mL three-neck flask and heated to 70 °C for reflux for 4 h to form a transparent ferric oleate complexes solution. After that, the liquid was separated by a separation funnel and the upper oil layer was preserved. Hexane in the liquid evaporated at 70 °C by rotating evaporation and dried for 48 h under vacuum. The prepared samples were stored in a vacuum glove box for further use.

Synthesis of Fe3O4 NPs

We synthesized Fe3O4 NPs following previously reported procedures with slight modification [46]. Ferric oleate (7.2 g), OA (1.28 mL), and ODE (50 mL) were mixed together in a 100-mL three-neck flask and heated to 300 °C for 40 min under argon protection; after that, the mixture was cooled to room temperature and oxidized in air for more than 12 h. The resultant nanocrystals were precipitated by the addition of isopropanol, centrifuged, and washed twice with an ethanol–water mixture (1:1 v/v). The oleic acid-capped Fe3O4 NPs were finally dispersed in 200 mL cyclohexane, and the supernatant was sealed and stored for the subsequent experiments.

Preparation of Fe3O4 NCs

Fe3O4 NCs were prepared by a facile and straightforward microemulsion self-assembly technique as previously described with modification [47]. Briefly, a 200-μL solution of Fe3O4 nanocrystals in cyclohexane was poured into 4 mL of aqueous solution containing 14 mg of SDBS. The mixed solution underwent ultrasonic treatment for 5 min for 4 times. The formed solid-in-oil-in-water (S/O/W) emulsion was stirred at room temperature for 6 h to evaporate the organic solvent following by the self-assembly of Fe3O4 NPs to form 3D NCs. The final products were washed with deionized water 3 times to remove the excess SDBS, unincorporated nanocrystals, and some possible larger contaminants.

Preparation of Fe3O4 NC/PAH/PSS/DOX Hybrid Nanostructures

The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were prepared by electrostatic attractive interactions. The as-prepared Fe3O4 NCs are negatively charged owing to the encapsulation of the anionic surfactants. They were first turned to be positively charged by adsorption of a layer of positively charged polyelectrolyte, poly(allylamine hydrochloride) (PAH, MW 15 000). Specifically, a 300-μL Fe3O4 NC sample was firstly diluted 10 times to 3 mL using deionized water. The Fe3O4 NC mixture was subsequently added dropwise to an aqueous PAH solution (1 mL, 10 g/L, 4 mM NaCl) under vigorous stirring. After the solution was stirred for 24 h, the excess PAH was removed by centrifugation, and the resultant PAH-coated Fe3O4 NCs (Fe3O4 NC/PAH) were redispersed in water (3 mL).

The Fe3O4 NC/PAH were then turned to be negatively charged by adsorption of a layer of negatively charged polyelectrolyte, poly-(sodium 4-styrenesulfonate) (PSS, MW 70 000). Specifically, a 3-mL Fe3O4 NC/PAH sample solution was added dropwise to an aqueous PSS solution (1 mL, 10 g/L, 4 mM NaCl) under vigorous stirring. After the solution was stirred for 24 h, the excess PSS was removed by centrifugation, and the resultant PSS-coated Fe3O4 NC/PAH (Fe3O4 NC/PAH/PSS) were redispersed in water (3 mL).

The DOX aqueous stock solution was first prepared [17]. The concentration was 5.0 mg/mL. The hybrid nanostructure solution was obtained by mixing the Fe3O4 NC/PAH/PSS solution (3 mL, 32 mg/mL) and the stock DOX solution (60 μL) in a small plastic tube with stirring for 24 h in the darkroom. After centrifugation, the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were obtained finally.

MRI Measurements

The MRI measurements were performed in an 11.7 T micro 2.5 micro-imaging system (Bruker, Germany). The different amount of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were dispersed in 1.2 mL agarose aqueous solution and then loaded into the microtubes for MRI measurements. The final Fe ion concentration were 0 mM, 0.013 mM, 0.026 mM, 0.032 mM, 0.041 mM, 0.052 mM, and 0.065 mM, respectively. The measurement parameters are as follows: repetition time (TR) = 300 ms, echo time (TE) = 4.5 ms, imaging matrix = 128 × 128, slice thickness = 1.2 mm, field of view (FOV) = 2.0 × 2.0 cm, and number of averages (NA) = 2.

Cellular Uptake and MR Imaging

To demonstrate efficient cellular uptake, the A549 cells were seeded on the coverslip in the confocal dish and incubated in a humidified 5% CO2 atmosphere for 4 h at 37 °C. Then, the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were added into the incubation medium at the different concentration and incubated for 2 h. The final Fe ion concentrations were obtained as 0, 2.2, 4.5, 9.0, and 13.5 μM, respectively. After the medium was removed, the cells were washed twice with PBS (pH = 7.4, 20 mM) and directly used for MR imaging.

Standard Curve of DOX

A suitable quantity of DOX was dissolved in water by oscillation. Then, a series of different concentrations of DOX aqueous solution were prepared (0–0.03 mg/mL). The fluorescence intensity of different concentrations of DOX solution was measured (λex = 490 nm). Finally, the standard curve of DOX was determined through the curve fitting of the fluorescence intensity vs the DOX concentration.

The area standard curve: Y = 447.4423 + 69745.08457X.

Precision rate of standard curve: R2 = 0.9992.

DOX Loading and Release

To measure the loading capacities of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, the supernatant solution was collected after centrifugation of the as-prepared hybrid nanostructures. The fluorescence spectrum of DOX molecules in the supernatant solution was examined and the concentration of DOX in the supernatant was calculated by comparing the standard curve of DOX. The percentages of DOX remaining in the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were calculated according to the following equation:

$$ \mathrm{Loading}\ \mathrm{efficiency}\ \left(\%\right)=\left({\mathrm{W}}_0\hbox{-} {\mathrm{W}}_{\mathrm{s}}\right)/{\mathrm{W}}_0\times 100\% $$

where W0 and Ws represent the initial DOX mass and the DOX mass in the supernatants, respectively.

For the cumulative DOX release studies in PBS buffer solutions (pH 5.0 and 7.4) with the same NaCl concentration of 0.15 M, the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were dispersed in 1.0 mL of buffer solution and then transferred into a dialysis bag. Then, it was kept in buffer solution and gently shaken at 37 °C in the darkroom. At selected time intervals, 100 μL of solution was withdrawn and analyzed by fluorescence spectrum, and then returned to the original solution.

In Vitro Cytotoxicity of Fe3O4 NC/PAH/PSS/DOX Hybrid Nanostructures

In vitro cytotoxicity of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures was assessed against A549 cells based on the standard methyl thiazolyltetrazolium (MTT) assay. A549 cells were cultured in APMI 1640 growth medium complemented with 10% fetal bovine serum (FBS), streptomycin at 100 μg/mL, and penicillin at 100 μg/mL. The cells were maintained at 37 °C in a humidified atmosphere of 5% CO2 in air. The assay was performed in triplicate with the same manner. Briefly, A549 cells were seeded into 96-well plates at a density of 8 × 103 cells per wells in 100 μL of media. After overnight growth, the cells were then incubated at various concentrations of free DOX, Fe3O4 NC/PAH/PSS, and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures (0.1, 0.2, 0.4, 0.8, 1.2, 1.6, 2.0 μM) for 24 h. After being incubated for 24 h, the 10 μL 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (5 mg/mL) was then added each well and the cells were further incubated for 4 h at 37 °C. After the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution was removed, 150 μL of dimethyl sulfoxide (DMSO) was added to each well and the plate was gently shaken for 10 min to dissolve the precipitated violet crystals. The optical density (OD) was measured at 490 nm using microplate reader (Perkin Elmer, Victor X4). Cell viability was evaluated as a percentage compared to control cells.

Characterization

The sizes and morphologies of Fe3O4 NPs and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were examined by a FEI Tecnai G2-F20 transmission electron microscope (TEM) at an accelerating voltage of 200 kV. Dynamic light scattering (DLS) measurements were performed on a particle size and zeta potential analyzer from Malvern (Zetasizer Nano ZS90). The UV–vis absorption spectra were acquired by a Perkin Elmer Lambda-25 UV–vis spectrometer. The fluorescence spectra were recorded using a Hitachi F-4600 fluorescence spectrophotometer. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) (Agilent 5100) was used to analyze the element Fe concentrations in the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures.

Results and Discussion

The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures are prepared by self-assembly of primary iron oxide (Fe3O4) NPs resulting into densely packed spherical aggregates through a microemulsion self-assembly technique as previously described with modification [17, 47], following by a LBL electrostatic adsorption method. Figure 1 illustrates the schematic illustration of synthesis of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. Hydrophobic oleic acid-coated magnetite Fe3O4 NPs were initially produced by the thermal decomposition process in organic solvent [46]. Fe3O4 NPs are spherical and uniform in size with an average particle size of about 15 nm (Additional file 1: Figure S1). For the assembly of magnetic NCs, the OA-coated Fe3O4 NPs were dispersed in cyclohexane and then added dropwise to an aqueous solution containing SDBS. The complex solution was ultrasonically treated to form a stable oil-in-water emulsion. After the evaporation of organic solvent in the emulsion, Fe3O4 NPs were self-assembled to form spherical nanoclusters via hydrophobic interaction. Next, the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were prepared via a LBL method through electrostatic attractive interactions, which is schematically illustrated in Fig. 1.

Fig. 1
figure1

Schematic illustration of synthesis of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures as theranostic agents for MRI and drug delivery

The morphologies and sizes of the Fe3O4 NCs and the Fe3O4 NC/PAH/PSS hybrid nanostructures were examined with TEM and DLS, respectively. As shown in Fig. 2a and b, the Fe3O4 NCs demonstrate the quasi-spherical clusters. The average particle size measured by DLS is about 57 nm (Fig. 2e). In previous reports, PAH with positive charge or PSS with negative charge is alternately deposited on the template surface due to their excellent electrostatic properties [48,49,50,51]. To study the formation of each polyelectrolyte layer deposited on the Fe3O4 NCs, the zeta potential experiments were performed. The variation of zeta potential with the polyelectrolyte layer for PSS/PAH and DOX coatings are shown in Additional file 1: Figure S2. The pristine Fe3O4 NCs have a negative zeta-potential of − 19.7 mV due to the existence of SDBS. The absorption of a positively charged PAH single layer on Fe3O4 NCs reverses the surface potential from − 19.7 to + 32 mV. Subsequently, deposition of the negatively charged PSS layer causes another surface potential reversion from + 32 to − 34 mV. This indicates a stepwise layer growth during the fabrication of the magnetic NC hybrid nanostructures. These results show that the PAH and PSS layers were successfully coated on the Fe3O4 NCs. Finally, DOX was successfully adsorbed on the surface of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, which was confirmed by the positive zeta potential (+ 1.91 mV) (Additional file 1: Figure S2). The TEM images with a different magnification of the Fe3O4 NC/PAH/PSS hybrid nanostructures are shown in Fig. 2c and d. No significant structural and morphology difference is observed after polyelectrolyte coatings. Compared with Fig. 2a and b, the bright contrast can be observed and the size of the Fe3O4 NC/PAH/PSS hybrid nanostructures is increased slightly owing to the coating of PAH and PSS layers. The synthesized magnetic hybrid nanostructures show a nearly mono-dispersed quasi-spherical shape with average size of about 84 nm according to the results of DLS measurement (Fig. 2f).

Fig. 2
figure2

TEM images of Fe3O4 NCs (a, b) and Fe3O4 NC/PAH/PSS (c, d) at lower and higher magnification, respectively. Size distribution of Fe3O4 NCs (e) and Fe3O4 NC/PAH/PSS hybrid nanostructures (f)

To evaluate the potential application of Fe3O4 NC/PAH/PSS hybrid nanostructures in MRI, the proton transverse relaxation rates (1/T2) as a function of Fe ion concentration were determined using Bruker AVANCE 500WB spectrometer at 11.7 T. A linear relationship between relaxation rates with Fe ion concentration was observed, as shown in Fig. 3b. Furthermore, the transverse relaxation rates (1/T2) increased with increasing concentration of Fe3O4 NCs due to the high degree of aggregation of the Fe3O4 magnetic NPs core, demonstrating that the magnetic hybrid nanostructures could be an effective T2-weighted MRI contrast agent (Fig. 3a). Based on the slope of the plot in Fig. 3b, the transverse relaxivity value (r2) was determined to be 651.38 mM−1S−1, which is higher than that of the reported work [22]. Compared with commercial T2 contrast media, the nanoclusters can significantly improve the contrast ability of Fe after the magnetic NPs self-assembled on the basis of collective effect, thus greatly improving the angiographic effect. In the previous work, the assembled magnetite nanocrystals exhibited a higher level of saturation magnetization than individual nanocrystals due to the collective effect of magnetic nanocrystals [43, 52].

Fig. 3
figure3

a T2-weighted MRI images of the Fe3O4 NC/PAH/PSS hybrid nanostructures at different concentrations in water. b Plot of relaxation rate r2 versus Fe concentration in Fe3O4 NC/PAH/PSS hybrid nanostructures. The relaxivity value r2 was obtained from the slope of the linear fitting of the experimental data

To evaluate the drug loading capacity of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures as drug delivery carriers, a water-soluble anticancer drug (DOX) was chosen as a model drug. The storage of DOX in the hybrid nanostructures with a high efficiency was first revealed by the color change of the solution. The color of the solution of Fe3O4 NC/PAH/PSS and the pure DOX solution was yellowish and red, respectively (Fig. 4a and b). After forming of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, the color of the solution became orange (Fig. 4c). Owing to the presence of Fe3O4 NPs, the DOX-loaded nanostructures in the suspension could be separated by an external magnet, suggesting that the great potential of the obtained hybrid nanostructures for magnetically targeted drug delivery (Fig. 4d). UV–vis absorption spectroscopy was used to determine the effective DOX storage capacity. Figure 4e shows the UV–vis absorption spectra of the DOX aqueous solution before and after the interaction with Fe3O4 NC/PAH/PSS hybrid nanostructures. Compared with free DOX, the similar absorption peak characteristics were observed in the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, which is the recombination absorption peak of Fe3O4 NCs and DOX. The sample without DOX only shows the absorption peak of Fe3O4 NCs. These data indicate that DOX as a drug can be successfully absorbed onto the surface of the hybrid nanostructures. It is also found that there is an upper limit of adsorption concentration of DOX loaded on the surface of the hybrid nanostructures. Figure 4f shows the PL spectrum of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures after centrifugation when different concentrations of DOX were added into the Fe3O4 NC/PAH/PSS solution. The luminescence intensity of DOX increases as an increase of added DOX until reaching a ceiling (8 mg/mL) with the concentration of Fe3O4 NC/PAH/PSS (1.30 × 10−2 mg/mL) unchanged. Afterwards, the entrapment amount decreases because of the excess DOX, which cannot be adsorbed on the surface of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. The strongest fluorescence intensity of DOX corresponds to the concentration at 8 mg/mL, and the corresponding sample would be used for further study to perform biomedical experiment. The assured drug loading efficiency of the hybrid nanostructures is crucial for the clinical application. The loading efficiency was calculated by the area integral of DOX fluorescence intensity using the standard curve method of DOX [53, 54]. The loading efficiency was calculated up to 24.39% for the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. Therefore, a theranostic platform has been built up based on the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures due to the effective absorption of antitumor drug DOX.

Fig. 4
figure4

Photographs (ad) of the different absorbed stages of DOX on the Fe3O4 NC/PAH/PSS hybrid nanostructures. The UV–vis absorption spectra (e) of DOX, Fe3O4 NC/PAH/PSS, and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. The luminescence spectra (f) of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures when the different concentration of DOX was added into the Fe3O4 NC/PAH/PSS hybrid nanostructure solution

The in vitro drug-releasing profiles of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures under various environmental pH values are demonstrated in Fig. 5. The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were dialyzed through a dialysis membrane in phosphate buffers at 37 °C. The released DOX from the hybrid nanostructures was collected and then the release amount of DOX was calculated by fluorescence intensity of the supernatant. At physiological pH 7.4, the observed drug release is a slow release process. About 20 wt% of DOX was released at the initial 5 h, and then entered the stable stage of slow release. At pH 5.0, about 80 wt% of DOX was released from the hybrid nanostructures at the initial 15 h before a release plateau was reached. The plateau percentages of DOX release observed over a period of 30 h were 80 ± 3 wt% and 20 ± 3 wt% at pH 5.0 and 7.4, respectively. It can be seen that the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures have been revealed a sustained release profile and a higher DOX release rate at pH 5.0 than at pH 7.4. The low environment pH accelerates the DOX release from the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. That is due to the protonation of the –NH2 group of DOX under acidic conditions, which reduces the electrostatic interaction between DOX and PSS polymers at low pH values [55]. The drug release studies indicate the good stability of electrostatically bound drug molecules in physiological pH and the triggered release at acidic conditions, similar to the reported works [56,57,58]. Therefore, the obtained Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures are the pH-responsive systems for DOX drug delivery and suitable for the specific treatment of solid tumors [59].

Fig. 5
figure5

Plot of the release of DOX from the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures in PBS buffer at pH 7.4 and 5.0, respectively

The cellular uptake and cytotoxicity are key factors to evaluate the potential of a new drug delivery system. The cellular uptake and cytotoxicity of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures on A549 cell lines were studied. The intercellular uptake of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures was investigated using optical and fluorescence microscopy, which was mainly realized by monitoring the fluorescence from DOX. The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures have been proved to be effective in delivering DOX to cancer cells. As shown in Fig. 6, strong red fluorescence from DOX was observed in cancer cells after incubation for 24 h. The hybrid nanostructures were internalized mainly through endocytosis [60]. After cell uptake, the hybrid nanostructures released DOX in the acidic environment around the endosome/lysosomes, in which a sufficiently low pH (4.3) could trigger an effective DOX release (pH 5.0, Fig. 5). The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures exhibited time-dependent uptake in A549 cancer cells, as shown in Fig. 6. At 0.5 h post incubation, red fluorescence was visible around the cells. The results show that the hybrid nanostructures containing DOX mainly stayed around the A549 cells. However, when the incubation time increased to 24 h, the intercellular fluorescence signal increased from the A549 cells. Obviously, many hybrid nanostructures can enter the cancer cells over time. These results confirm that the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures can efficiently transfer DOX into A549 cells. DOX released from the hybrid nanostructures in the cytoplasm passes through the nuclear membrane and eventually accumulates in the nucleus, killing cells by causing changes in DNA conformation [61].

Fig. 6
figure6

Confocal fluorescence microscopic images of A549 cells incubated with the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures at 37 °C for a 0.5 h and b 24 h. Scale bar, 20 μm

In order to evaluate the pharmacological activity of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, the cytotoxicity to A549 cells in vitro was determined by MTT method. Figure 7 shows the cell activity of free DOX, Fe3O4 NC/PAH/PSS, and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures with different concentrations after incubation with A549 cells for 24 h. The material amounts were calculated according to the concentration of DOX. The free DOX concentration was the same as the DOX concentration in Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, and the concentration of Fe3O4 NC/PAH/PSS hybrid nanostructure was the same as the Fe3O4 NC/PAH/PSS concentration in the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. Each sample was cultured with A549 cells for 24 h. The concentration of Fe3O4 NC/PAH/PSS ranged from 0.1 to 2.0 μΜ, and the cell survival rate exceeded 85%. This indicated that Fe3O4 NC/PAH/PSS hybrid nanostructures had no obvious cytotoxicity to cancer cells and had good biocompatibility. After incubating with cancer cells for 24 h, however, the free DOX and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures showed obvious cytotoxicity. The cellular viability progressively decreased with increasing effective DOX concentration. As shown in Fig. 7, when the effective DOX concentration was increased from 0.1 up to 2.0 μM, the relative cell viability decreased from about 92% to about 50% for free DOX, and from about 89% to about 40 % for Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, respectively.

Fig. 7
figure7

Relative viability of A549 cells incubated with free DOX, Fe3O4 NC/PAH/PSS, and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures at different concentrations for 24 h. Error bars were based on triplicate samples

These results indicate that both free DOX and Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures have dose-dependent cytotoxicity to cancer cells. The cytotoxicity originates from the loaded DOX rather than Fe3O4 NC/PAH/PSS hybrid nanostructures. Cell uptake of free DOX is faster than that of DOX-loaded hybrid nanostructures. This reason is that small DOX molecules can quickly spread into cells, while Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures must be endocytosis in order to enter cancer cells. Because of the hypoxia-induced coordinated upregulation of glycolysis, the acidic extracellular environment of solid tumors is stronger than that of normal tissues [62]. At the cellular level, the internalization of most of the hybrid nanostructures will take place through endocytosis. With the increase of DOX concentration, more and more hybrid nanostructures loaded with DOX are endocytosed into cancer cells. After cellular endocytosis, the DOX-loaded hybrid nanostructures usually enter the early endosomes, then enter the late endosomes/lysosomes, and finally fused with lysosomes. Furthermore, both endosomes (pH 5.0–6.0) and lysosomes (pH 4.5–5.0) have an acidic microenvironment. In our study, the pH-responsive Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were more likely to decompose and release drugs in acidic environments, thus effectively reducing side effects, prolonging half-life of drugs, and providing more effective and lasting treatment. Due to the main target of DOX being cell nucleus, DOX can bind to double-stranded DNA to form DNA adducts, inhibit the activity of topoisomerase and induce cell death (apoptosis) [63]. As a result, the released DOX molecules were located in the cell nucleus. Therefore, the obtained Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures may have good potential for cancer chemotherapy.

As discussed above, the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures exhibit high relaxivity in aqueous solution and can be uptaken efficiently by A549 cells. The intracellular MRI of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were then investigated by incubation of A549 cells with the hybrid nanostructures with different Fe3O4 concentrations. Figure 8 presents the T2-weighted MRI of A549 cells. With the increase of Fe3O4 concentration in Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures, the cellular MRI signal increased gradually (Fig. 8). Currently, cell labeling is mainly accomplished by the endocytosis of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures as T2-negative contrast agents. These results demonstrate that the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures can be internalized into cells and exhibit good T2-weighted MRI contrast for cellular imaging. Our current research is limited to the cellular level. Future in vivo studies would be necessary for the practical application of the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures. To specially target a specific site in animal studies, small ligands such as lactic acid and folic acid (both containing carboxyl groups) would require to be used to conjugate amino-terminated Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures.

Fig. 8
figure8

T2-weighted cellular MR images of A549 cells incubated with the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures at a Fe concentration of 2.2, 4.5, 9.0, and 13.5 μM, respectively

Conclusion

The multifunctional Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures were developed as the pH-triggered drug delivery system for effective cancer chemotherapy and MRI. The quasi-spherical Fe3O4 NCs can significantly improve the contrast ability of MRI compared with Fe3O4 NPs. The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures can act as contrast agents to enhance MRI and as a fluorescence probe for cell imaging. The DOX can be released from the Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures at acidic environment and exhibit an excellent cellular cytotoxic effect on A549 cells. The Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures as multifunctional theranostic platform have great potential for biomedical application, including MRI, fluorescence imaging, and stimuli-responsive drug delivery nanocarriers.

Availability of Data and Materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Please contact the author for data requests.

Abbreviations

1/T 2 :

The proton transverse relaxation rates

A549:

Human lung cancer

DLS:

Dynamic light scattering

DMSO:

Dimethyl sulfoxide

DOX:

Doxorubicin hydrochloride

FBS:

Fetal bovine serum

Fe3O4 :

Iron oxide

FOV:

Field of view

LBL:

Layer-by-layer

MRI:

Magnetic resonance imaging

MTT:

Methyl thiazolyltetrazolium

NA:

Number of averages

NaOA:

Sodium oleate

NaOH:

Sodium hydroxide

NC:

Nanocluster

NCs:

Nanoclusters

NH4F:

Ammonium fluoride

NPs:

Nanoparticles

OA:

Oleic acid

OD:

Optical density

ODE:

1-Octadecene

PAH:

Poly(allylamine hydrochloride)

PSS:

Poly(sodium 4-styrenesulfonate)

S/O/W:

Solid-in-oil-in-water

SDBS:

Sodium dodecyl benzene sulfonate

TE:

Echo time

TEM:

Transmission electron microscope

TR:

Repetition time

References

  1. 1.

    Kim J, Kim HS, Lee N, Kim T, Kim H, Yu T et al (2008) Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed. 47:8438–8441

  2. 2.

    Xia A, Gao Y, Zhou J, Li C, Yang T, Wu D et al (2011) Core-shell NaYF4:Yb3+,Tm3+@FexOy nanocrystals for dual-modality T 2-enhanced magnetic resonance and NIR-to-NIR upconversion luminescent imaging of small-animal lymphatic node. Biomaterials. 32:7200–7208

  3. 3.

    Chen Y, Chen H, Zhang S, Chen F, Zhang L, Zhang J et al (2011) Multifunctional mesoporous nanoellipsoids for biological bimodal imaging and magnetically targeted delivery of anticancer drugs. Adv Funct Mater. 21:270–278

  4. 4.

    Lee JH, Chen KJ, Noh SH, Garcia MA, Wang H, Lin WY et al (2013) On-demand drug release system for in vivo cancer treatment through self-assembled magnetic nanoparticles. Angew Chem Int Ed. 52:4384–4388

  5. 5.

    Bogart LK, Pourroy G, Murphy CJ, Puntes V, Pellegrino T, Rosenblum D et al (2014) Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano. 8:3107–3122

  6. 6.

    Doane TL, Burda C (2012) The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev. 41:2885–2911

  7. 7.

    Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Accounts Chem Res. 44:853–862

  8. 8.

    Lee JE, Lee N, Kim H, Kim J, Choi SH, Kim JH et al (2010) Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc. 132:552–557

  9. 9.

    Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L et al (2008) Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 108:2064–2110

  10. 10.

    Wang X, Hu H, Zhang H, Li C, An B, Dai J (2018) Single ultrasmall Mn2+-doped NaNdF4 nanocrystals as multimodal nanoprobes for magnetic resonance and second near-infrared fluorescence imaging. Nano Res. 11:1069–1081

  11. 11.

    Hu Y, Mignani S, Majoral J-P, Shen M, Shi X (2018) Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. Chem Soc Rev. 47:1874–1900

  12. 12.

    Li L, Liu C, Zhang L, Wang T, Yu H, Wang C et al (2013) Multifunctional magnetic-fluorescent eccentric-(concentric-Fe3O4@SiO2)@polyacrylic acid core-shell nanocomposites for cell imaging and pH-responsive drug delivery. Nanoscale. 5:2249–2253

  13. 13.

    Tian Y, Jiang X, Chen X, Shao Z, Yang W (2014) Doxorubicin-loaded magnetic silk fibroin nanoparticles for targeted therapy of multidrug-resistant cancer. Adv Mater. 26:7393–7398

  14. 14.

    Wei T, Liu J, Ma H, Cheng Q, Huang Y, Zhao J et al (2013) Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 13:2528–2534

  15. 15.

    Chen H, Qi B, Moore T, Wang F, Colvin DC, Sanjeewa LD et al (2014) Multifunctional yolk-in-shell nanoparticles for pH-triggered drug release and imaging. Small. 10:3364–3370

  16. 16.

    Pilapong C, Keereeta Y, Munkhetkorn S, Thongtem S, Thongtem T (2014) Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles. Colloid Surface B. 113:249–253

  17. 17.

    Zhao J, Yang H, Li J, Wang Y, Wang X (2017) Fabrication of pH-responsive PLGA(UCNPs/DOX) nanocapsules with upconversion luminescence for drug delivery. Sci Rep. 7:18014

  18. 18.

    Zhao J, Wu J, Xue J, Zhu Q, Ni W (2016) Au/NaYF4: Yb, Er binary superparticles: synthesis and optical properties. Isr J Chem. 56:242–248

  19. 19.

    Hong X, Li J, Wang M, Xu J, Guo W, Li J et al (2004) Fabrication of magnetic luminescent nanocomposites by a layer-by-layer self-assembly approach. Chem Mater. 16:4022–4027

  20. 20.

    Zhang L, Zhou N, Wang B, Liu C, Zhu G (2014) Fabrication of Fe3O4/PAH/PSS@Pd core-shell microspheres by layer-by-layer assembly and application in catalysis. J Colloid Interf Sci. 421:1–5

  21. 21.

    Abbaszad Rafi A, Mahkam M (2015) Preparation of magnetic pH-sensitive microcapsules with an alginate base as colon specific drug delivery systems through an entirely green route. RSC Adv. 5:4628–4638

  22. 22.

    Ge R, Li X, Lin M, Wang D, Li S, Liu S et al (2016) Fe3O4@polydopamine composite theranostic superparticles employing preassembled Fe3O4 nanoparticles as the core. ACS Appl Mater Interfaces. 8:22942–22952

  23. 23.

    Yan K, Li H, Li P, Zhu H, Shen J, Yi C et al (2014) Self-assembled magnetic fluorescent polymeric micelles for magnetic resonance and optical imaging. Biomaterials. 35:344–355

  24. 24.

    Wang X, Zhang Q, Zhao J, Dai J (2013) One-step self-assembly of ZnPc/NaGdF4:Yb,Er nanoclusters for simultaneous fluorescence imaging and photodynamic effects on cancer cells. J Mater Chem B. 1:4637–4643

  25. 25.

    Huang S, Cheng Z, Chen Y, Liu B, Deng X, Ma PA et al (2015) Multifunctional polyelectrolyte multilayers coated onto Gd2O3:Yb3+,Er3+@MSNs can be used as drug carriers and imaging agents. RSC Adv. 5:41985–41993

  26. 26.

    Zhou Z, Song J, Tian R, Yang Z, Yu G, Lin L et al (2017) Activatable singlet oxygen generation from lipid hydroperoxide nanoparticles for cancer therapy. Angew Chem Int Ed. 129:6492–6496

  27. 27.

    Tian X, Zhang L, Yang M, Bai L, Dai Y, Yu Z et al (2017) Functional magnetic hybrid nanomaterials for biomedical diagnosis and treatment. WIREs Nanomed Nanobiotechnol. 10:e1476

  28. 28.

    Nosrati H, Sefidi N, Sharafi A, Danafar H, Kheiri MH (2018) Bovine serum albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug. Bioorg Chem. 76:501–509

  29. 29.

    Zhi WT, Chandrasekharan P, Zhou XY, Yu E, Bo Z, Conolly S (2018) In vivo tracking and quantification of inhaled aerosol using magnetic particle imaging towards inhaled therapeutic monitoring. Theranostics. 8:3676–3687

  30. 30.

    Chandra Mohanta S, Saha A, Sujatha Devi P (2018) PEGylated iron oxide nanoparticles for pH responsive drug delivery application. Mater Today: Proceedings. 5:9715–9725

  31. 31.

    Wang D, Rogach AL, Caruso F (2002) Semiconductor quantum dot-labeled microsphere bioconjugates prepared by stepwise self-assembly. Nano Lett. 2:857–861

  32. 32.

    Schneider G, Decher G (2008) Functional core/shell nanoparticles via layer-by-layer assembly. Investigation of the experimental parameters for controlling particle aggregation and for enhancing dispersion stability. Langmuir. 24:1778–1789

  33. 33.

    Luo R, Neu B, Venkatraman SS (2012) Surface functionalization of nanoparticles to control cell interactions and drug release. Small. 8:2585–2594

  34. 34.

    Ni W, Yang Z, Chen H, Li L, Wang J (2008) Coupling between molecular and plasmonic resonances in freestanding dye–gold nanorod hybrid nanostructures. J Am Chem Soc. 130:6692–6693

  35. 35.

    Ni W, Chen H, Su J, Sun Z, Wang J, Wu H (2010) Effects of dyes, gold nanocrystals, pH, and metal ions on plasmonic and molecular resonance coupling. J Am Chem Soc. 132:4806–4814

  36. 36.

    Jin Y, Gao X (2009) Plasmonic fluorescent quantum dots. Nat Nanotechnol. 4:571–576

  37. 37.

    Wang L, Yang Z, Zhang Y, Wang L (2010) Bifunctional nanoparticles with magnetization and luminescence. J Phys Chem C. 113:3955–3959

  38. 38.

    Rui Xu GS, Li Q, Wang E, Gu J (2010) A dual-responsive superparamagnetic Fe3O4/Silica/PAH/PSS material used for controlled release of chemotherapeutic agent, keggin polyoxotungstate, PM-19. Solid State Sci. 12:1720–1725

  39. 39.

    Wang X, Zhang Q, Zou L, Hu H, Zhang M, Dai J (2016) Facile-synthesized ultrasmall CuS nanocrystals as drug nanocarriers for highly effective chemo–photothermal combination therapy of cancer. RSC Adv. 6:20949–20960

  40. 40.

    Jin J, Hines WA, Kuo C-H, Perry DM, Poyraz AS, Xia Y et al (2015) Magnetic studies of mesoporous nanostructured iron oxide materials synthesized by one-step soft-templating. Dalton T. 44:11943–11953

  41. 41.

    Bao Y, Sherwood JA, Sun Z (2018) Magnetic iron oxide nanoparticles as T 1 contrast agents for magnetic resonance imaging. J Phys Chem C. 6:1280–1290

  42. 42.

    Zhao Y, Zhao X, Cheng Y, Guo X, Yuan W (2018) Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharmaceut. 15:1791–1799

  43. 43.

    Zhou Z, Tian R, Wang Z, Yang Z, Liu Y, Liu G et al (2017) Artificial local magnetic field inhomogeneity enhances T 2 relaxivity. Nat Commun. 8:15468

  44. 44.

    Chen O, Riedemann L, Etoc F, Herrmann H, Coppey M, Barch M et al (2014) Magneto-fluorescent core-shell supernanoparticles. Nat Commun. 5:5093–5098

  45. 45.

    Wu C-H, Cook J, Emelianov S, Sokolov K (2014) Multimodal magneto-plasmonic nanoclusters for biomedical applications. Adv Funct Mater. 24:6862–6871

  46. 46.

    Sun S, Zeng H (2002) Size-controlled synthesis of magnetite nanoparticles. J Am Chem Soc. 124:8204–8205

  47. 47.

    Bai F, Wang D, Huo Z, Chen W, Liu L, Liang X et al (2007) A versatile bottom-up assembly approach to colloidal spheres from nanocrystals. Angew Chem Int Ed. 46:6650–6653

  48. 48.

    Zhang H, Li Y, Ivanov IA, Qu Y, Huang Y, Duan X (2010) Plasmonic modulation of the upconversion fluorescence in NaYF4:Yb/Tm hexaplate nanocrystals using gold nanoparticles or nanoshells. Angew Chem Int Ed. (16):2927–2930

  49. 49.

    Chen H, Moore T, Qi B, Colvin DC, Jelen EK, Hitchcock DA et al (2013) Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence. ACS Nano. 7:1178–1187

  50. 50.

    Nagaraja AT, Sooresh A, Meissner KE, McShane MJ (2013) Processing and characterization of stable, pH-sensitive layer-by-layer modified colloidal quantum dots. ACS Nano. 7:6194–6202

  51. 51.

    Tian L, Chen E, Gandra N, Abbas A, Singamaneni S (2012) Gold nanorods as plasmonic nanotransducers: distance-dependent refractive index sensitivity. Langmuir. 28:17435–17442

  52. 52.

    Park JW, Bae KH, Kim C, Park TG (2011) Clustered magnetite nanocrystals cross-linked with PEI for efficient siRNA delivery. Biomacromolecules. 12:457–465

  53. 53.

    Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 161:505–522

  54. 54.

    Mittal G, Sahana DK, Bhardwaj V, Kumar MNVR (2007) Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 119:77–85

  55. 55.

    Venkatesan R, Pichaimani A, Hari K, Balasubramanian PK, Kulandaivel J, Premkumar K (2013) Doxorubicin conjugated gold nanorods: a sustained drug delivery carrier for improved anticancer therapy. J Mater Chem B. 1:1010–1018

  56. 56.

    Wei F, Zhou X, He C, Qiu K, Wei N, Liang C et al (2013) Polyelectrolyte multilayer functionalized mesoporous silica nanoparticles for pH-responsive drug delivery: Layer thickness-dependent release profiles and biocompatibility. J Mater Chem B. 1:5886–5898

  57. 57.

    Xie L, Tong W, Yu D, Xu J, Li J, Gao C (2012) Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery. J Mater Chem. 22:6053–6060

  58. 58.

    Xin W, Qian Z, Li Z, Hu H, Dai J (2016) Facile-synthesized ultrasmall CuS nanocrystals as drug nanocarries for highly effective chemo-photothermal combination therapy of cancer. RSC Adv. 6:20949–20960

  59. 59.

    Zheng F, Wang S, Shen M, Zhu M, Shi X (2013) Antitumor efficacy of doxorubicin-loaded electrospun nano-hydroxyapatite–poly (lactic-co-glycolic acid) composite nanofibers. Polym Chem-UK. 4:933–941

  60. 60.

    Song L, Ho VHB, Chen C, Yang Z, Liu D, Chen R et al (2013) Efficient, pH-triggered drug delivery using a ph-responsive dna-conjugated gold nanoparticle. Adv Healthc Mater. 2:275–280

  61. 61.

    Husain N, Agbaria RA, Warner IM (1993) Spectroscopic analysis of the binding of doxorubicin to human .alpha.-1 acid glycoprotein. J Phys Chem. 97:10857–10861

  62. 62.

    Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 6:15–19

  63. 63.

    Zhang Z-Y, Xu Y-D, Ma Y-Y, Qiu L-L, Wang Y, Kong J-L et al (2013) Biodegradable ZnO@polymer core-shell nanocarriers: pH-triggered release of doxorubicin in vitro. Angew Chem Int Ed. 52:4127–4131

Download references

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (Nos.11774384, 11174324, and 11204122) for the synthesis of materials, the Youth Innovation Promotion Association of Chinese Academy of Sciences (Nos.2011235) for the synthesis of materials, the characterizations of the as-synthesized samples, the Natural Science Research Project of the Education Department of Henan Province (Grant no.12B430016), and the Science and Technology Development Program of Henan Province (Nos.172102210402), Henan Provincial Youth Backbone Teachers (Nos.2015GGJS-110) for analysis of the data.

Author information

JZ and XW (corresponding author) contributed to the analysis of the data and writing the manuscript. XL carried out the synthesis of materials and the characterizations of the as-synthesized samples. XW contributed to the discussion and analysis of the data. XW (corresponding author) contributed to the conception and design of the experiment. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Correspondence to Xin Wang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Figure S1. TEM image of Fe3O4 nanoparticles. Figure S2. Zeta potential at the different synthesis stages of Fe3O4 NC/PAH/PSS/DOX hybrid nanostructures as theranostic agents for magnetic resonance imaging and drug delivery. (DOCX 399 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, J., Li, X., Wang, X. et al. Fabrication of Hybrid Nanostructures Based on Fe3O4 Nanoclusters as Theranostic Agents for Magnetic Resonance Imaging and Drug Delivery. Nanoscale Res Lett 14, 200 (2019) doi:10.1186/s11671-019-3026-7

Download citation

Keywords

  • Fe3O4
  • Nanoclusters
  • DOX
  • Self-assembly
  • Hybrid nanostructures
  • Drug delivery